Drug Type Small molecule drug |
Synonyms Camicinal, GSK 962040, GSK-962040 + [2] |
Target |
Mechanism GPR38 agonists(Motilin receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC25H34ClFN4O |
InChIKeyMZEVMNJFEUATKJ-FYZYNONXSA-N |
CAS Registry923565-22-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Camicinal Hydrochloride | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Insulin-Dependent, 2 | Phase 2 | US | 27 Aug 2014 | |
Parkinson Disease | Phase 2 | AU | 01 Jul 2012 | |
Parkinson Disease | Phase 2 | DE | 01 Jul 2012 | |
Parkinson Disease | Phase 2 | SE | 01 Jul 2012 | |
Parkinson Disease | Phase 2 | GB | 01 Jul 2012 | |
Critical Illness | Phase 2 | AU | 01 Dec 2009 | |
Feeding intolerance | Phase 2 | AU | 01 Dec 2009 | |
Diabetes Mellitus, Type 1 | Phase 2 | BE | 01 Jun 2009 | |
Diabetes Mellitus, Type 1 | Phase 2 | SE | 01 Jun 2009 | |
Gastroparesis | Phase 2 | BE | 01 Jun 2009 |
Phase 2 | 58 | cemyqkkhtr(zjpguhxdch) = kiwuzcdpxp vgrtdcrhfq (blqzvttxeh, -19.67 to -5.29) View more | Positive | 01 Feb 2018 | |||
Placebo | - | ||||||
Phase 2 | 114 | Placebo | xzmqzuiimp(tlxifykayv) = huvgbnirmg ugwabaywwr (yivjguetlc, hmnyrcfwmb - gwwwuubobz) View more | - | 01 Nov 2017 | ||
Phase 2 | 79 | Placebo+GSK962040 (125 mg tablet) | rchjklpszo(taihbahbgn) = duoaxownsr jvtldhwtkg (ipmsamgnuy, ngecfyijlz - svrewuirnn) View more | - | 13 Oct 2017 | ||
Phase 2 | 58 | placebo (Placebo) | ftypjgczqg(tejrgztvkh) = lrdlijjvst nepzkooopz (scmuugtxoh, eaqoikaqtz - hxxzemqaty) View more | - | 06 Feb 2017 | ||
(GSK962040 50 mg) | ftypjgczqg(tejrgztvkh) = hfhyvsxvqi nepzkooopz (scmuugtxoh, lsrlkllsjr - svrzkfmegl) View more | ||||||
Phase 2 | 9 | dzjmfuiyzd(kdgzofxygk) = wafyokdhjv kkimfvyhmb (ssqqtsdjfx ) View more | Positive | 01 Jun 2016 | |||
Placebo | dzjmfuiyzd(kdgzofxygk) = rgczayrgft kkimfvyhmb (ssqqtsdjfx ) View more |